Other new selective MET-inhibitors, such as volitinib, savolitinib, and tepotinib, are currently being tested together with EGFR-TKIs in phase I/II trials for patients with advanced NSCLC [133,134]. The gene discussed is MET; the disease is non-small cell lung carcinoma.